Estrogen Supplementation Is Associated With Higher Quality of Life Scores in Women With Cystic Fibrosis

Abstract Purpose: With rapid advancements in therapeutic options for patients with cystic fibrosis (CF), the median predicted survival has increased to 47 years along prevalence of non-pulmonary complications CF. Women CF suffer irregular menses, sexual dysfunction and low bone mineral density. increasing pregnancies among women CF, they may consider contraception. Estrogen supplementation modulate these outcomes others. The purpose this study was explore effects supplemental estrogen use on quality life (QOL) Methods: ages 16-50 were administered a validated CF-specific QOL survey (CFQ-R) during routine clinic visit through an IRB-approved cross-sectional study. domain scores subjects taking not compared pairwise by Kruskal Wallis tests overall Wilcoxon signed rank test. Results: exposed unexposed had similar age, BMI, FEV1, race, mutation, pancreatic insufficiency, diabetes relationship status. 20-30 mcg ethinyl estradiol oral contraceptive pills. consistently higher than (p=0.001). significantly 7 12 CFQ-R categories: physical, vitality, treatment burden role domains weight, respiratory digestion symptom scales (p<0.05). When correcting multiple comparisons, estrogen-supplemented supplement (p=0.03). Conclusions: associated improved This highlights need further investigation into potential benefits supplementation. dose, route, formulation timing therapy beneficial Support: work supported National Center Advancing Translational Sciences Institutes Health under award TL1TR002382 UL1TR002378, Cystic Fibrosis Foundation WU20D0. content is solely responsibility authors does necessarily represent official views NIH or CFF.